174_CD GlaxoSmithKline_NNP Shareholder_NN return_NN Share_NN price_NN Dividends_NNS per_IN share_NN As_IN a_DT guide_NN to_TO shareholders_NNS ,_, the_DT table_NN below_IN sets_NNS out_IN the_DT dividends_NNS 2004 2003 2002_CD per_IN share_NN paid_VBN in_IN the_DT last_JJ five_CD years_NNS ._.
Dividends_NNS paid_VBD to_TO Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP The_NNP companys_VBZ share_NN price_NN decreased_VBN by_IN five_CD per_IN cent_NN in_IN 2004_CD shareholders_NNS are_VBP expressed_VBN as_IN dividends_NNS per_IN GlaxoSmithKline_NNP from_IN a_DT price_NN of_IN 12.80_CD at_IN 1st_CD January_NNP 2004_CD to_TO 12.22_CD at_IN share_NN ._.
This_DT compares_VBZ with_IN an_DT increase_NN in_IN the_DT FTSE_NNP 100_CD index_NN of_IN eight_CD per_IN cent_NN during_IN the_DT year_NN ._.
Dividends_NNS per_IN ADS_NNPS As_IN a_DT guide_NN to_TO holders_NNS of_IN ADRs_NNS ,_, the_DT table_NN below_IN sets_NNS out_IN the_DT Market_NN capitalization_NN dividends_NNS per_IN ADS_NNPS paid_VBN in_IN US_NNP dollars_NNS in_IN the_DT last_JJ five_CD years_NNS ._.
They_PRP The_DT market_NN capitalization_NN of_IN GlaxoSmithKline_NNP at_IN 31st_CD December_NNP are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN applicable_JJ exchange_NN rates_NNS ._.
At_IN that_DT date_NN GlaxoSmithKline_NNP was_VBD the_DT fourth_JJ largest_JJS company_NN by_IN market_NN capitalization_NN on_IN the_DT FTSE_NNP Year_NN GSK_NNP $_$ GW_CD $_$ SB_CD $_$ index_NN ._.
2004_CD 1.53_CD 2003_CD 1.39_CD SmithKline_NNP Beecham_NNP plc_NN Floating_VBG Rate_NNP Unsecured_NNP Loan_NNP Stock_NNP 2002_CD 1.24_CD 1990 2010 2001_CD 1.11_CD 2000_CD 1.10_CD 0.87_CD The_DT loan_NN stock_NN is_VBZ not_RB listed_VBN on_IN any_DT exchange_NN but_CC holders_NNS may_MD require_VB SmithKline_NNP Beecham_NNP plc_NN to_TO redeem_VB their_PRP$ loan_NN stock_NN at_IN Dividends_NNPS paid_VBD to_TO Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP par_NN ,_, i._FW e._FW 1_CD for_IN every_DT 1_CD of_IN loan_NN stock_NN held_VBN ,_, on_IN the_DT first_JJ business_NN ADR_NNP holders_NNS are_VBP expressed_VBN as_IN dividends_NNS per_IN GlaxoSmithKline_NNP day_NN of_IN March_NNP ,_, June_NNP ,_, September_NNP and_CC December_NNP ._.
One_CD GlaxoSmithKline_NNP ADS_NNPS represents_VBZ two_CD GlaxoSmithKline_NNP to_TO redeem_VB all_DT or_CC part_NN of_IN their_PRP$ loan_NN stock_NN should_MD complete_VB the_DT shares_NNS ._.
notice_NN on_IN the_DT back_NN of_IN their_PRP$ loan_NN stock_NN certicate_NN and_CC return_VB it_PRP to_TO the_DT registrar_NN ,_, to_TO arrive_VB at_IN least_JJS 30_CD days_NNS before_IN the_DT relevant_JJ Dividend_NN calendar_NN redemption_NN date_NN ._.
Fourth_JJ quarter_NN 2004_CD Taxation_NNP Ex-dividend_NN date_NN 16th_JJ February_NNP 2005_CD Record_NNP date_NN 18th_JJ February_NNP 2005_CD General_NNP information_NN concerning_VBG the_DT UK_NNP and_CC US_NNP tax_NN effects_NNS of_IN Payable_JJ 7th_JJ April_NNP 2005_CD share_NN ownership_NN is_VBZ set_VBN out_RP in_IN `_`` Taxation_NNP information_NN for_IN shareholders_NNS '_POS on_IN page_NN 178_CD ._.
First_JJ quarter_NN 2005_CD Dividends_NNPS Ex-dividend_NN date_NN 11th_JJ May_NNP 2005_CD Record_NNP date_NN 13th_JJ May_NNP 2005_CD GlaxoSmithKline_NNP pays_VBZ dividends_NNS quarterly_RB ._.
The_DT Board_NNP declared_VBD Payable_JJ 7th_JJ July_NNP 2005_CD dividends_NNS for_IN 2004_CD as_IN follows_VBZ :_: 2004_CD 2003_CD Second_JJ quarter_NN 2005_CD Dividends_NNPS per_IN share_NN pence_NN pence_NN Ex-dividend_NN date_NN 3rd_CD August_NNP 2005_CD First_NNP interim_JJ paid_VBN 1st_CD July_NNP 2004_CD 10_CD 9_CD Record_NNP date_NN 5th_JJ August_NNP 2005_CD Second_JJ interim_JJ paid_VBN 30th_JJ September_NNP 2004_CD 10_CD 9_CD Payable_JJ 6th_JJ October_NNP 2005_CD Third_NNP interim_JJ paid_VBN 6th_JJ January_NNP 2005_CD 10_CD 9_CD Fourth_JJ interim_JJ payable_JJ 7th_JJ April_NNP 2005_CD 12_CD 14_CD Third_JJ quarter_NN 2005_CD Total_JJ 42_CD 41_CD Ex-dividend_NN date_NN 2nd_JJ November_NNP 2005_CD Record_NNP date_NN 4th_JJ November_NNP 2005_CD Payable_JJ 5th_JJ January_NNP 2006_CD
